SIXPEX MASTE ENANTHATE 200

Sixpex Maste Enanthate 200 (Drostanolone Enanthate 200mg) | NexorinPharma

Sixpex Maste Enanthate 200 is an injectable anabolic steroid containing 200mg of Drostanolone Enanthate per milliliter. At NexorinPharma, we carry Sixpex Maste Enanthate 200 as part of our injectable anabolic steroid inventory for customers in markets where Drostanolone Enanthate is legally available.

Drostanolone Enanthate is the active compound in Sixpex Maste Enanthate 200. It is the long-acting ester form of Drostanolone, an anabolic steroid widely referenced in bodybuilding and performance communities under the brand name Masteron. The enanthate ester produces a half-life of approximately 10 to 12 days, making it a long-acting preparation requiring less frequent administration compared to the shorter-acting Drostanolone Propionate form.

Like all anabolic-androgenic steroids, Sixpex Maste Enanthate 200 carries significant health and legal considerations. This page covers what Drostanolone Enanthate is, how it works, and what health and legal considerations apply. It does not constitute medical advice. It does not recommend or encourage steroid use. It does not provide dosage, cycle, or stacking guidance of any kind.

Product Specifications

Website: nexorinpharma.com Product Name: Sixpex Maste Enanthate 200 Manufacturer: Sixpex Active Compound: Drostanolone Enanthate Also Known As: Masteron Enanthate, Mast E, Drostanolone E Drug Class: Anabolic-androgenic steroid, DHT derivative, injectable Concentration: 200mg per milliliter Presentation: Injectable solution Form: Oil-based injectable Half-Life: Approximately 10 to 12 days Ester: Enanthate Route of Administration: Intramuscular injection Anabolic Rating: 62 to 130 relative to testosterone baseline of 100 Androgenic Rating: 25 to 40 relative to testosterone baseline of 100 Aromatization: None Anti-Estrogenic Activity: Mild aromatase inhibition 17-Alpha Alkylated: No Liver Toxicity: Low Legal Status: Schedule III controlled substance in the United States. Prescription required. Legal status varies by country.

About Sixpex

Sixpex is a non-prescription anabolic steroid manufacturer producing injectable and oral anabolic steroid products for markets where such compounds are legally available. The brand carries a presence in international bodybuilding and performance communities and produces its product range with pharmaceutical-style presentation and clear compound labeling.

Like all manufacturers operating outside regulated pharmaceutical channels, Sixpex does not carry the manufacturing oversight, regulatory scrutiny, or clinical trial documentation of pharmaceutical grade prescription products. Consequently, quality, purity, and concentration accuracy are less verifiable than with regulated products. Within the non-prescription market, Sixpex is referenced for product presentation and labeling clarity.

What Is Drostanolone Enanthate

Drostanolone is a synthetic anabolic-androgenic steroid derived from Dihydrotestosterone. Syntex developed it in the 1950s and it was introduced to the market under the brand name Masteron. From the beginning, it was developed with a specific clinical application in mind: the treatment of inoperable breast cancer in women. This clinical origin distinguishes Drostanolone from many other anabolic steroids developed primarily for performance or general anabolic applications.

Structurally, Drostanolone is a DHT derivative with a methyl group at the second carbon position of the steroid structure. This modification prevents the compound from being metabolized by the 3-hydroxysteroid dehydrogenase enzyme in muscle tissue, preserving its anabolic activity. As a DHT derivative, Drostanolone does not convert to estrogen through the aromatase enzyme pathway. In addition, it carries mild aromatase inhibiting properties, partially reducing estrogen conversion from other aromatizing compounds.

The enanthate ester attached to the base Drostanolone compound determines its release rate and duration of activity. Enanthate is a long-acting ester producing a half-life of approximately 10 to 12 days. As a result, Sixpex Maste Enanthate 200 provides sustained Drostanolone plasma concentrations with less frequent administration compared to Drostanolone Propionate.

How Drostanolone Enanthate Works

After intramuscular injection, the oil-based preparation deposits at the injection site. Enzymes in the body gradually separate the enanthate ester from the Drostanolone molecule. Free Drostanolone then enters the bloodstream and becomes active throughout the body.

Androgen Receptor Binding

Drostanolone binds to androgen receptors throughout the body. Its androgenic activity is moderate compared to testosterone. As a result, androgen receptor activation in muscle tissue drives its anabolic effects while producing comparatively lower androgenic activity in androgen-sensitive tissues compared to testosterone-based compounds.

Nitrogen Retention

Drostanolone Enanthate produces positive nitrogen retention in muscle tissue. The body retains more nitrogen than it excretes. Consequently, this supports an anabolic environment that favors muscle repair and preservation. This mechanism contributes to the lean muscle maintenance observations consistently discussed in performance communities about Drostanolone use.

Protein Synthesis

Drostanolone Enanthate accelerates protein synthesis in skeletal muscle tissue. Faster protein synthesis supports muscle repair and maintenance. This mechanism is directly tied to its androgen receptor activity and contributes to its anabolic profile.

No Aromatization

Drostanolone Enanthate does not convert to estrogen through the aromatase enzyme pathway. As a DHT derivative, it is not a substrate for aromatase. Consequently, estrogen-related side effects including water retention and gynecomastia are not part of its direct pharmacological profile. This characteristic is one of the most consistently referenced pharmacological distinctions of Drostanolone in performance community discussions.

Mild Aromatase Inhibition

Drostanolone carries mild aromatase inhibiting properties. By partially inhibiting the aromatase enzyme, it reduces the rate of estrogen conversion from other aromatizing compounds present in the body. This mild anti-estrogenic activity is moderate compared to dedicated aromatase inhibitors such as Anastrozole or Exemestane. However, it is a pharmacologically relevant characteristic that distinguishes Drostanolone from most other anabolic steroids.

No Progestogenic Activity

Drostanolone Enanthate does not show clinically significant affinity for progesterone receptors. This distinguishes it from compounds like Trenbolone and Nandrolone where progestogenic activity is a primary side effect consideration. As a result, Sixpex Maste Enanthate 200 carries a cleaner overall side effect profile compared to progestogenic anabolic steroids.

Clinical Background

Drostanolone carries a documented clinical history that provides relevant context for its pharmacological profile and distinguishes it from many anabolic steroids discussed in performance communities.

Breast Cancer Treatment

Drostanolone was developed and used clinically for the treatment of inoperable breast cancer in women. Its anti-estrogenic properties through mild aromatase inhibition and androgen receptor activity made it a relevant clinical compound for hormone-sensitive breast cancer management. This clinical application gave Drostanolone a documented medical history that most anabolic steroids discussed in performance communities do not carry.

Clinical Withdrawal

Drostanolone’s clinical use for breast cancer treatment has largely been replaced by more modern targeted hormone therapies including selective estrogen receptor modulators and dedicated aromatase inhibitors. As a result, it is no longer widely used in clinical oncology settings in most markets. Its continued presence in performance communities developed independently of its clinical application history.

About the 200mg Concentration

The 200mg per milliliter concentration of Sixpex Maste Enanthate 200 is the standard concentration for Drostanolone Enanthate preparations in non-prescription markets. This higher concentration per milliliter compared to Drostanolone Propionate preparations, which are commonly produced at 100mg per milliliter, reflects the longer-acting enanthate ester’s lower injection frequency requirements.

Non-Prescription Market Context

Sixpex Maste Enanthate 200 is produced for markets where Drostanolone Enanthate is legally available. It does not carry the manufacturing oversight, regulatory scrutiny, or clinical documentation of pharmaceutical grade prescription products. Quality, purity, and concentration accuracy are consequently less verifiable than with regulated products.

Comparison With Drostanolone Propionate

Drostanolone Propionate uses the short-acting propionate ester with a half-life of approximately 2 to 3 days. It requires significantly more frequent administration than Drostanolone Enanthate to maintain stable plasma concentrations. Sixpex Maste Enanthate 200, on the other hand, uses the longer-acting enanthate ester with a half-life of approximately 10 to 12 days. As a result, it requires less frequent injection while delivering the same active Drostanolone compound.

Sixpex Maste Enanthate 200 Versus Other Injectable Anabolic Steroids

Versus Drostanolone Propionate

Both preparations contain Drostanolone as the active compound and carry identical pharmacological profiles. The distinction is the ester. Drostanolone Propionate uses the short-acting propionate ester with a half-life of approximately 2 to 3 days. Sixpex Maste Enanthate 200 uses the longer-acting enanthate ester with a half-life of approximately 10 to 12 days. Consequently, Sixpex Maste Enanthate 200 requires less frequent injection while producing the same Drostanolone-mediated pharmacological effects.

Versus Methenolone Enanthate (Primobolan Depot)

Both Drostanolone Enanthate and Methenolone Enanthate are non-aromatizing DHT derivative injectable anabolic steroids using the enanthate ester. Both carry mild side effect profiles compared to most injectable anabolic steroids. However, Drostanolone carries mild aromatase inhibiting properties that Methenolone does not. In addition, Drostanolone’s androgenic activity is more pronounced than Methenolone’s. As a result, both compounds are referenced in performance communities for non-aromatizing profiles but with distinct pharmacological differences.

Versus Testosterone Enanthate

Testosterone Enanthate uses the same enanthate ester as Sixpex Maste Enanthate 200, producing a comparable half-life. However, testosterone aromatizes to estrogen while Drostanolone does not. Testosterone carries an anabolic rating of 100 and androgenic rating of 100, while Drostanolone carries significantly lower ratings. As a result, Sixpex Maste Enanthate 200 produces a milder anabolic profile with a significantly cleaner estrogenic side effect picture compared to Testosterone Enanthate.

Versus Trenbolone Enanthate

Trenbolone Enanthate uses the same enanthate ester but carries anabolic and androgenic ratings of 500 each compared to Drostanolone’s significantly lower ratings. Trenbolone also shows progestogenic activity and produces a significantly more aggressive side effect profile than Drostanolone. Sixpex Maste Enanthate 200 consequently represents a considerably milder pharmacological profile than Trenbolone Enanthate across virtually all parameters.

Versus Boldenone Undecylenate

Boldenone Undecylenate is a long-acting injectable anabolic steroid with moderate aromatization. Drostanolone Enanthate does not aromatize and carries mild anti-estrogenic properties. Both compounds carry moderate anabolic profiles. However, Sixpex Maste Enanthate 200 carries a cleaner estrogenic side effect profile compared to Boldenone Undecylenate due to its complete absence of aromatization and mild aromatase inhibiting activity.

Side Effects and Health Risks

Sixpex Maste Enanthate 200 carries a side effect profile that is generally considered milder than most injectable anabolic steroids. These risks remain real and should not be minimized.

Androgenic Effects

Despite its relatively moderate androgenic rating, Drostanolone Enanthate still produces androgenic side effects in susceptible individuals. These include accelerated hair loss in genetically predisposed individuals and acne on the face and back. In women, virilization effects including voice deepening and changes in body hair distribution are serious considerations even with milder androgenic compounds.

Cardiovascular Effects

Drostanolone Enanthate produces adverse lipid profile changes. HDL cholesterol decreases while LDL cholesterol increases. These lipid changes carry long-term cardiovascular health implications. Regular lipid monitoring is therefore important for anyone using this compound despite its milder overall side effect profile.

Hormonal Suppression

Drostanolone Enanthate suppresses the hypothalamic-pituitary-gonadal axis and the body’s natural testosterone production. The degree of suppression is generally considered less pronounced than with more potent anabolic steroids. However, post-use hormonal disruption remains a relevant consideration. In some cases, it results in hypogonadism requiring medical treatment.

Injection Site Reactions

As an oil-based intramuscular injectable, Sixpex Maste Enanthate 200 carries injection site risks including pain, swelling, and in rare cases infection. Proper injection technique and sterile practices are therefore essential for anyone using this preparation.

Psychological Effects

Anabolic steroid use carries documented associations with mood changes and irritability. These considerations apply to Drostanolone Enanthate use. They are generally less pronounced than with higher androgenic compounds but remain relevant health considerations.

Legal and Regulatory Status

Drostanolone Enanthate carries Schedule III controlled substance status in the United States under the Controlled Substances Act. Possession without a valid prescription is a federal offense.

In the United Kingdom, Drostanolone Enanthate falls under Class C of the Misuse of Drugs Act. Supply is illegal.

The World Anti-Doping Agency bans Drostanolone Enanthate alongside all major athletic governing bodies. It consequently appears on prohibited substance lists across Olympic sports, professional athletics, and competitive bodybuilding organizations that conduct testing.

You are responsible for confirming the legal status of Drostanolone Enanthate in your specific jurisdiction before purchasing from NexorinPharma.

Frequently Asked Questions

Is Sixpex Maste Enanthate 200 Available at NexorinPharma

Yes. NexorinPharma carries Sixpex Maste Enanthate 200 for customers in markets where Drostanolone Enanthate is legally available. Visit nexorinpharma.com to check current availability and pricing.

What Is the Half-Life of Sixpex Maste Enanthate 200

The enanthate ester produces a half-life of approximately 10 to 12 days. As a result, Sixpex Maste Enanthate 200 provides sustained Drostanolone plasma concentrations with less frequent administration compared to Drostanolone Propionate.

Does Drostanolone Enanthate Aromatize

No. Drostanolone Enanthate does not convert to estrogen through the aromatase enzyme pathway. As a DHT derivative, it is not a substrate for aromatase. Furthermore, it carries mild aromatase inhibiting properties that partially reduce estrogen conversion from other aromatizing compounds.

How Does Sixpex Maste Enanthate 200 Compare to Drostanolone Propionate

Both preparations contain Drostanolone as the active compound and carry identical pharmacological profiles. The distinction is the ester and injection frequency. Drostanolone Propionate produces a half-life of approximately 2 to 3 days and requires more frequent administration. Sixpex Maste Enanthate 200 produces a half-life of approximately 10 to 12 days and requires less frequent injection.

What Are the Most Serious Health Risks

Cardiovascular effects from lipid dysregulation and hormonal suppression are the most clinically significant concerns with Drostanolone Enanthate. Androgenic effects, injection site reactions, and psychological impacts complete the primary risk profile. Medical supervision and regular blood work monitoring are therefore essential for anyone using this compound.

Is Sixpex Maste Enanthate 200 Legal to Purchase

Drostanolone Enanthate carries Schedule III controlled substance status in the United States and requires a valid prescription. Legal status varies by jurisdiction. You are responsible for confirming the legal status in your jurisdiction before purchasing from NexorinPharma.

What to Consider Before Purchasing Sixpex Maste Enanthate 200

Drostanolone Enanthate has a documented clinical history in breast cancer treatment and a well-established presence in bodybuilding and performance community discussions. Its non-aromatizing profile, mild anti-estrogenic properties, and relatively favorable side effect profile compared to most injectable anabolic steroids contribute to its consistent discussion in performance communities.

The Sixpex non-prescription format does not carry the manufacturing oversight of pharmaceutical grade products. The clinical and observational research base for Drostanolone applies to its pharmacological profile and risk profile regardless of the specific manufacturer or format. Furthermore, the side effect profile documented in research applies regardless of the milder reputation this compound carries relative to other anabolic steroids.

Drostanolone Enanthate carries documented cardiovascular, hormonal, androgenic, and psychological health risks. These risks require medical supervision to manage responsibly. Consulting a licensed medical professional is the appropriate starting point for anyone with health concerns related to anabolic steroid use.

For customers in markets where Drostanolone Enanthate is legally available, visit nexorinpharma.com to check current Sixpex Maste Enanthate 200 availability, pricing, and stock levels.